DE69726450D1 - Mucosale verabreichung von wirkstoffen in säugern - Google Patents

Mucosale verabreichung von wirkstoffen in säugern

Info

Publication number
DE69726450D1
DE69726450D1 DE69726450T DE69726450T DE69726450D1 DE 69726450 D1 DE69726450 D1 DE 69726450D1 DE 69726450 T DE69726450 T DE 69726450T DE 69726450 T DE69726450 T DE 69726450T DE 69726450 D1 DE69726450 D1 DE 69726450D1
Authority
DE
Germany
Prior art keywords
mammals
mucosal administration
active substances
natural polymer
biovector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69726450T
Other languages
English (en)
Other versions
DE69726450T2 (de
Inventor
Didier Betbeder
Alain Etienne
Miguel Ignacio De
Roger Kravtzoff
Michel Major
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ceva Sante Animale SA
Original Assignee
Ceva Sante Animale SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ceva Sante Animale SA filed Critical Ceva Sante Animale SA
Publication of DE69726450D1 publication Critical patent/DE69726450D1/de
Application granted granted Critical
Publication of DE69726450T2 publication Critical patent/DE69726450T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/778—Nanostructure within specified host or matrix material, e.g. nanocomposite films
    • Y10S977/783—Organic host/matrix, e.g. lipid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/795—Composed of biological material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/797—Lipid particle
    • Y10S977/798—Lipid particle having internalized material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/797—Lipid particle
    • Y10S977/798—Lipid particle having internalized material
    • Y10S977/799—Containing biological material
    • Y10S977/80—Nucleic acid, e.g. DNA or RNA
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/797—Lipid particle
    • Y10S977/798—Lipid particle having internalized material
    • Y10S977/799—Containing biological material
    • Y10S977/801—Drug
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/827—Nanostructure formed from hybrid organic/inorganic semiconductor compositions
    • Y10S977/83—Inorganic core or cluster coated with organic or biological shell
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y10S977/917—Vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69726450T 1996-12-27 1997-12-09 Mucosale verabreichung von wirkstoffen in säugern Expired - Fee Related DE69726450T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/774,920 US6096291A (en) 1996-12-27 1996-12-27 Mucosal administration of substances to mammals
US774920 1996-12-27
PCT/IB1997/001647 WO1998029099A2 (en) 1996-12-27 1997-12-09 Mucosal administration of substances to mammals

Publications (2)

Publication Number Publication Date
DE69726450D1 true DE69726450D1 (de) 2004-01-08
DE69726450T2 DE69726450T2 (de) 2004-09-16

Family

ID=25102698

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69726450T Expired - Fee Related DE69726450T2 (de) 1996-12-27 1997-12-09 Mucosale verabreichung von wirkstoffen in säugern

Country Status (15)

Country Link
US (2) US6096291A (de)
EP (1) EP0948322B1 (de)
JP (1) JP2001507358A (de)
KR (1) KR20000062350A (de)
AT (1) ATE254911T1 (de)
AU (1) AU739512B2 (de)
BR (1) BR9713792A (de)
CA (1) CA2275419C (de)
DE (1) DE69726450T2 (de)
DK (1) DK0948322T3 (de)
ES (1) ES2212145T3 (de)
HK (1) HK1025042A1 (de)
HU (1) HUP0001838A3 (de)
IL (1) IL130507A0 (de)
WO (1) WO1998029099A2 (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
DK1039931T3 (da) * 1997-12-01 2005-08-08 Fang Fang Multivalente rekombinante antistoffer til at behandle HRV infektioner
FR2771929B1 (fr) * 1997-12-09 2001-02-23 Biovector Therapeutics Utilisation dans une composition pharmaceutique pour l'administration par voie nasale de particules hydrophiles pour la delivrance d'agents actifs au systeme nerveux central
US7097849B2 (en) * 1998-08-19 2006-08-29 Jagotec Ag Injectable aqueous dispersions of propofol
US20070178139A1 (en) * 1998-11-18 2007-08-02 Yankov Vladimir I Vaginally administratable progesterone-containing tablets and method for preparing same
IL127129A (en) * 1998-11-18 2004-06-01 Ferring Bv Method for preparation of progesterone tablets for vaginal delivery and tablets so prepared
US20030035798A1 (en) * 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
EP2481401A1 (de) 1999-01-18 2012-08-01 LG Life Sciences, Ltd. Lipophile Mikropartikel mit einem Proteinarzneimittel oder Antigen und Formulierung damit
US20050232868A1 (en) * 1999-10-19 2005-10-20 The Procter & Gamble Company Methods of entrapping, inactivating, and removing viral infections by the administration of respiratory tract compositions
US20040234457A1 (en) * 1999-10-19 2004-11-25 The Procter & Gamble Company Methods of preventing and treating SARS using low pH respiratory tract compositions
US7785625B2 (en) 2000-01-14 2010-08-31 Lg Life Sciences, Limited Lipophilic-coated microparticle containing a protein drug and formulation comprising same
WO2001068828A2 (en) 2000-03-13 2001-09-20 Engene, Inc. Compositions and methods for regulated protein expression in gut
WO2001070763A1 (en) * 2000-03-22 2001-09-27 The Children's Hospital Of Philadelphia Modified blood clotting factors and methods of use
FR2808193B1 (fr) * 2000-04-26 2004-05-07 Biovector Therapeutics Utilisation de l'il-2 et de vecteurs synthetiques dans le traitement des cancers
EP1276468A1 (de) * 2000-04-26 2003-01-22 Biovector Therapeutics S.A. Verwendung teilchenförmiger vektoren in der immunomodulation
DE60128910T2 (de) 2000-04-27 2008-02-28 Verion Inc. Nullte-ordnung-freisetzung und temperatur-kontrollierte mikrokapseln sowie herstellungsverfahren
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US6368602B1 (en) * 2000-06-16 2002-04-09 Hadasit Medical Research Services And Development Ltd Mucosal immunization against hepatitis A virus (HAV) through rectal administration of HAV vaccine
US7527807B2 (en) * 2000-06-21 2009-05-05 Cubist Pharmaceuticals, Inc. Compositions and methods for increasing the oral absorption of antimicrobials
EP1343581A2 (de) 2000-09-27 2003-09-17 Verion Inc. Sofortige wasserlösliche kapsel und ihr herstellungsverfahren
US20020150621A1 (en) * 2000-10-16 2002-10-17 Kohane Daniel S. Lipid-protein-sugar particles for drug delivery
WO2002032396A2 (en) * 2000-10-16 2002-04-25 Massachusetts Institute Of Technology Lipid-protein-sugar particles for delivery of nucleic acids
US6663861B2 (en) 2000-11-09 2003-12-16 Antibodyshop A/S Method of producing antibodies by immunization with conjugates of molecules coupled to charge-modified proteins
US6838452B2 (en) 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
WO2002041827A2 (en) 2000-11-24 2002-05-30 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
US20020141946A1 (en) * 2000-12-29 2002-10-03 Advanced Inhalation Research, Inc. Particles for inhalation having rapid release properties
EP1353556A4 (de) * 2001-01-23 2009-09-09 Massachusetts Inst Technology Fest- und flüssigphasen-synthese von heparin und anderen glykosaminoglykanen
JP2004517103A (ja) * 2001-02-26 2004-06-10 カウンシル・オブ・サイエンティフィック・アンド・インダストリアル・リサーチ 薬剤、治療用ペプチド／タンパク質およびワクチンの経口送達のための新規なビタミンｂ１２−生物分解性微粒子状接合体キャリヤー系
GB0106403D0 (en) * 2001-03-15 2001-05-02 Pharmaceutical Profiles Labelling of dry powder formulations for inhalation
CA2898314A1 (en) 2001-07-19 2003-07-31 Perian Therapeutics, Inc. Multimeric proteins and methods of making and using same
MXPA04005865A (es) 2001-12-19 2004-09-13 Nektar Therapeutics Suministro de aminoglucosidos a los pulmones.
DE10200717A1 (de) 2002-01-10 2003-07-31 Knoell Hans Forschung Ev Verwendung von Polysaccharid-Derivaten als antiinfektive Substanzen
US20050170334A1 (en) * 2002-03-13 2005-08-04 Toshifumi Mikayama Human monoclonal antibodies to influenza M2 protein and methods of making and using same
AU2003223285A1 (en) * 2002-03-13 2003-09-29 Kirin Beer Kabushiki Kaisha Human monoclonal antibodies to influenza m2 protein and methods of making and using same
US7943179B2 (en) * 2003-09-23 2011-05-17 Massachusetts Institute Of Technology pH triggerable polymeric particles
US20050123596A1 (en) * 2003-09-23 2005-06-09 Kohane Daniel S. pH-triggered microparticles
US20060263350A1 (en) * 2003-09-26 2006-11-23 Fairfield Clinical Trials Llc Combination antihistamine medication
US7807847B2 (en) * 2004-07-09 2010-10-05 Vascular Biogenics Ltd. Process for the preparation of oxidized phospholipids
EP2574612A1 (de) 2004-07-09 2013-04-03 Vascular Biogenics Ltd. Verbessertes Verfahren zur Herstellung von oxidierten Phospholipiden
CA2606386C (en) * 2005-04-29 2014-06-10 Cubist Pharmaceuticals, Inc. Therapeutic compositions
WO2006131023A1 (en) * 2005-06-08 2006-12-14 Newbiomed Pika Pte Ltd Polyinosinic acid-polycytidylic acid-based adjuvant
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
WO2007065118A2 (en) * 2005-12-01 2007-06-07 Innograft, Llc Method for ionically cross-linking polysaccharide material for thin film applications and products produced therefrom
US20070166239A1 (en) * 2006-01-13 2007-07-19 Haixiang Lin Mucosal immunogenic substances comprising a polyinosinic acid - polycytidilic acid based adjuvant
US20070166800A1 (en) * 2006-01-13 2007-07-19 Haixiang Lin Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant
EP1897538A1 (de) * 2006-08-23 2008-03-12 Stallergenes Sa Formulierungen für Antigen-spezifische Toleranzinduktion
US9006217B2 (en) 2007-01-09 2015-04-14 Vascular Biogenics Ltd. High-purity phospholipids
US8569529B2 (en) 2007-01-09 2013-10-29 Vascular Biogenics Ltd. High-purity phospholipids
BRPI0905725B8 (pt) 2008-01-11 2021-05-25 Univ Emory vacina e embalagem farmacêutica
EP2348866B1 (de) * 2008-11-06 2015-01-07 Vascular Biogenics Ltd. Oxidierte lipidverbindungen und ihre verwendung
WO2010144865A2 (en) 2009-06-12 2010-12-16 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
AU2010279492B2 (en) 2009-08-04 2015-04-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of The Health And Human Services, Centers For Disease Control And Prevention Anti-RSV immunogens and methods of immunization
WO2011060233A1 (en) 2009-11-11 2011-05-19 The Trustees Of The University Of Pennsylvania Anti-tem1 antibodies and uses thereof
EP2506859B1 (de) * 2009-12-04 2016-05-04 Magle AB Mikrokugeln aus hydrolysierter stärke mit endogenen geladenen liganden
WO2011100408A2 (en) 2010-02-10 2011-08-18 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services, Centers For Disease Control And Prevention Serologic correlates of protection against bacillis anthracis infection
US9102742B2 (en) 2010-02-10 2015-08-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention Serologic correlates of protection against Bacillus anthracis infection
AU2011230619C1 (en) 2010-03-25 2016-06-23 Oregon Health & Science University CMV glycoproteins and recombinant vectors
EP2691530B1 (de) 2011-06-10 2018-03-07 Oregon Health & Science University Cmv-glycoproteine und rekombinante vektoren
US8514067B2 (en) 2011-08-16 2013-08-20 Elwha Llc Systematic distillation of status data relating to regimen compliance
EP2568289A3 (de) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunselektion von rekombinantem vesikulärem Stomatitisvirus mit Expression von HIV-1-Proteinen durch Breitbandneutralisierungs-Antikörper
US8965062B2 (en) * 2011-09-16 2015-02-24 The Invention Science Fund I, Llc Reporting imaged portions of a patient's body part
EP2586461A1 (de) 2011-10-27 2013-05-01 Christopher L. Parks Von einem eingehüllten Virus abgeleitete Virenpartikel
US9783610B2 (en) 2012-04-27 2017-10-10 The Trustees Of The University Of Pennsylvania Anti-tumor endothelial marker-1 (TEM1) antibody variants and uses thereof
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9771385B2 (en) 2014-11-26 2017-09-26 Vascular Biogenics Ltd. Oxidized lipids
ES2855299T3 (es) 2014-11-26 2021-09-23 Vascular Biogenics Ltd Lípidos oxidados y tratamiento o prevención de la fibrosis
EP3069730A3 (de) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
CN109142420B (zh) * 2018-10-12 2020-01-10 厦门大学 基于核磁共振技术探究药物在胶束内最大增溶量的方法
US11739166B2 (en) 2020-07-02 2023-08-29 Davol Inc. Reactive polysaccharide-based hemostatic agent
FR3112284B1 (fr) 2020-07-10 2024-02-09 Vaxinano Procede de preparation d’une composition vaccinale a partir d’antigenes lyophilises
IT202200004892A1 (it) 2022-03-14 2023-09-14 Sissa Scuola Int Superiore Di Studi Avanzati Dispositivo per l’erogazione di farmaci a base di grafene per la somministrazione mucosale e transmucosale

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4148876A (en) * 1975-09-29 1979-04-10 Burroughs Wellcome Co. Biological preparations
GB1564500A (en) * 1975-09-29 1980-04-10 Wellcome Found Biological preparations
US4196191A (en) * 1975-09-29 1980-04-01 Burroughs Wellcome Co. Biological preparations
US4921757A (en) * 1985-04-26 1990-05-01 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
US4900556A (en) * 1985-04-26 1990-02-13 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
US4925678A (en) * 1987-04-01 1990-05-15 Ranney David F Endothelial envelopment drug carriers
DE3722837A1 (de) * 1987-07-10 1989-01-19 Ruetgerswerke Ag Ophthalmisches depotpraeparat
FR2631826B1 (fr) * 1988-05-27 1992-06-19 Centre Nat Rech Scient Vecteur particulaire utile notamment pour le transport de molecules a activite biologique et procede pour sa preparation
GB9018690D0 (en) * 1990-08-24 1990-10-10 Wellcome Found Vaccines
DE4120760A1 (de) * 1991-06-24 1993-03-04 3 M Medica Gmbh Traegersysteme fuer arzneimittel
FR2702160B1 (fr) * 1993-03-02 1995-06-02 Biovecteurs As Vecteurs particulaires synthétiques et procédé de préparation.
US5354853A (en) * 1993-03-12 1994-10-11 Genzyme Corporation Phospholipid-saccharide conjugates
FR2704145B1 (fr) * 1993-04-21 1995-07-21 Pasteur Institut Vecteur particulaire et composition pharmaceutique le contenant.
FR2723849B1 (fr) * 1994-08-31 1997-04-11 Biovector Therapeutics Sa Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique
ES2170853T3 (es) * 1995-03-28 2002-08-16 Fidia Advanced Biopolymers Srl Nanosferas que comprenden un polisacarido biocompatible.

Also Published As

Publication number Publication date
HUP0001838A2 (hu) 2000-10-28
WO1998029099A2 (en) 1998-07-09
JP2001507358A (ja) 2001-06-05
DK0948322T3 (da) 2004-03-29
CA2275419C (en) 2006-10-03
AU5675698A (en) 1998-07-31
EP0948322A2 (de) 1999-10-13
ATE254911T1 (de) 2003-12-15
US6096291A (en) 2000-08-01
HK1025042A1 (en) 2000-11-03
CA2275419A1 (en) 1998-07-09
US6017513A (en) 2000-01-25
EP0948322B1 (de) 2003-11-26
AU739512B2 (en) 2001-10-11
BR9713792A (pt) 2000-02-08
ES2212145T3 (es) 2004-07-16
IL130507A0 (en) 2000-06-01
WO1998029099A3 (en) 1998-09-17
KR20000062350A (ko) 2000-10-25
DE69726450T2 (de) 2004-09-16
HUP0001838A3 (en) 2000-12-28

Similar Documents

Publication Publication Date Title
DE69726450D1 (de) Mucosale verabreichung von wirkstoffen in säugern
FI971776A0 (fi) Yhdisteet ja koostumukset aktiivisten aineiden antamiseksi
IT1286501B1 (it) Borati stabili agli acidi per la fotopolimerizzazione
EE9900481A (et) Väikesed molekulid, mida kasutatakse põletikuliste haiguste raviks
ES2044957T3 (es) Metodo para obtener una preparacion para administracion intranasal.
LU91758I2 (fr) Denosumab et ses dérivés pharmaceutiquement acceptables (PROLIA®)
ES2187659T3 (es) Tratamiento de la diabetes mellitus de tipo ii con agonistas de amilina.
DE69636104D1 (de) Orale pharmazeutische Zusammensetzung mit verzögerter Wirkstofffreigabe von Protonenpumpen-Hemmern
EA200000449A1 (ru) Модифицированные витамины к-зависимые полипептиды
DK0785948T3 (da) Analoger af keratinocyt vækstfaktor
FI885533A0 (fi) Polymerkomposition foer anvaendning som belaeggning foer elledningar och foerfarande foer belaeggning av elledningar.
EP0360077A3 (de) Verwendung von Serotonin-Antagonisten bei der Behandlung von Apoplexia cerebri
BR9808641B1 (pt) processo para preparação de uma forma de dosagem sólida, oral de rápida desintegração de uma substáncia farmaceuticamente ativa que possui um sabor inaceitável.
DK1167354T3 (da) Racemisk huperzin A
KR950700725A (ko) 리포솜 조성물(liposome composition)
EA199900580A1 (ru) Фармацевтические производные аминофосфоновой кислоты
IT8224665A0 (it) Acidi alfa-arilalcanoici e loro derivati in forma otticamente attiva, particolarmente utili come medicamenti e procedimento per laloro preparazione.
NO963749D0 (no) Transdermalt system i form av et plaster med et Tamoxifenderivat
IT1319275B1 (it) Uso del baclofen nel trattamento dell'astinenza da etanolo.
FI935051A (fi) Lanolinderivat som penetrationfraemjande aemnen och anvaendning av dessa i preparat innehaollande laekemedel eller andra biologiskt aktiva substanser
YU12397A (en) NOVEL PYRIMIDO [1,2-a] INDOLES
AR017216A1 (es) Metodo para regular la fagocitosis de celulas de mamiferos.
ES2136724T3 (es) Emulsion liofilizada, que contiene una sustancia activa.
ES2131308T3 (es) Composiciones y metodos que utilizan el receptor de mpl no ligado para estimular la produccion de plaquetas.
NO975127L (no) Anvendelse av ikke-steroidale antiinflammatoriske midler for å forbedre den fysiologiske forlikelighet av partikulære farmasöytiske preparater

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee